1. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в Российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечн. недостат. 2004; 5 (1): 4–7.
2. Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Сердечн. недостат. 2003; 4 (5).
3. Национальные рекомендации "Диагностика и лечение хронической сердечной недостаточности". Сердечн. недостат. 2007; 8 (2).
4. Национальные рекомендации "Диагностика и лечение артериальной гипертензии". Кардиоваск. тер. и проф. 2008; 7 (6). прил. 2.
5. Ольбинская Л.И., Сизова Ж.М. Хроническая сердечная недостаточность. М: Реафарм, 2002.
6. Отчет о научной сессии КНЦ РАМН Хроническая сердечная недостаточность от 21.01.1999 г. Кардиология. 1999; 12: 54–5.
7. Свищенко Е. Сердечная недостаточность у больных с артериальной гипертензией. Doctor. 2001; 4 (8): 40–4.
8. Фармакотерапия хронических сердечно-сосудистых заболеваний. Руководство для врачей. Под ред. акад. РАМН Л.И.Ольбинской. М.: ОАО "Издательство "Медицина", 2006.
9. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ 2006; 4: 45–50.
10. AIRE: The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors in acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8.
11. Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809–16.
12. Baker DW. Prevention of heart failure. J Card Fail. 2002; 8 (5): 333–46.
13. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999: 353: 9–13.
14. Cleland JGF, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP–CHF). Eur Heart J 2006; 27: 2338–45.
15. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator_Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96: 856–63.
16. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005; 7: 631–9.
17. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.
18. Lorell BH. Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin II: current concepts. Basic Research in Cardiology 1992; 87 (Suppl 2): 163–72.
19. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure; Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–6.
20. Packer M, Fowler MB. Roecker EB et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002; 106: 2194–9.
21. Pitt B, Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
22. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinipril vs amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
23. Thackray S, Witte K, Clark AL et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. Eur J Heart Fail 2000; 2: 209–12.
24. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987; 316: 1429–35.
25. The SOLVD investigators. Effect of enalapril on survivalin patients with reduced ejection fraction and congestive heart failure. New Engl J Med 1991; 325: 293–302.
26. Vetter W Treatment of senile hypertension. The Fosinopril in old patients study ( FOPS). Am J Hypertension 1997; 10: 255S–61S.
27. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 4.
28. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid alherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 2004; 35 (12): 2807–12.

Т.Е.Морозова, Т.Б.Андрущишина, А.Ю.Воложанина